Supplementary Table 1. Clinical and demographic characteristics of biologic drug-naive patients treated with Adalimumab and Baricitinib				
	All patients (n=133)	**Baricitinib (n=26)**	**Adalimumab (n=107)**	**p**
Female n (%)	102 (76.7)	20 (76.9)	82 (76.6)	0.97
Age (SD)	52.5 (13.3)	51.5 (13.6)	53.2 (13.7)	0.57
Disease duration, years (SD)	7.2 (7.9)	8.0 (9.3)	6.8 (7.4)	0.46
Disease duration at the time of the first biologic drug: years (SD)	6.3 (7.9)	7.5 (9.2)	5.9 (7.4)	0.32
Smoking (%)				**<0.001**
-Never	69/98 (70.4)	8/23 (34.8)	61/75 (81.3)	
-Ex-smoker or active smoker	14/29 (29.6)	15/23 (65.2)	14/75 (18.7)	
BMI (SD)	27.4 (5.4)	28.5 (5.6)	27.1 (5.3)	0.27
BMI ≥30 (%)	30/112 (26.8)	9/23 (39.1)	21/89 (23.6)	0.13
Coronary artery disease (%)	11/130 (8.5)	3/23 (13.0)	8 (7.5)	0.41
Early family history of CAD (%)	19/130 (14.6)	1/23 (4.3)	18 (16.8)	0.19
Percutaneous coronary intervention (%)	9/130 (6.9)	3/23 (13.0)	6 (5.6)	0.19
Bypass (%)	1/130 (0.8)	0	1 (0.9)	1
Hypertension (%)	38/130 (29.2)	8/23 (34.8)	30 (28.0))	0.51
Diabetes n (%)	24/130 (18.5)	4/23(17.4)	20 (18.7)	0.88
Hyperlipidemia n (%)	66/116 (56.9)	13/23 (56.5)	53/93 (57.0)	0.96
CKD n (%)	4/130 (3.1)	2/23 (8.7)	2 (1.9)	0.14
Infection requiring hospitalization (%)	21/130 (16.2)	3/23 (13.0)	18 (16.8)	0.65
History of cancer in first- and second-degree relatives	34/130 (26.2)	5/23 (21.7)	29 (27.1)	0.59
Positive RF n (%)	91/131 (69.5)	15/24 (62.5)	76 (71.0)	0.41
Positive CCP n (%)	73/120 (60.8)	18/22 (81.8)	55/98 (56.1)	**0.02**
RF or CCP positivity n (%)	100/131 (76.3)	20/24 (83.3)	80 (74.8)	0.37
Duration of medication, months (SD)	7.6 (8.7)	5.8 (7.1)	8.1 (9.0)	0.17
Monotherapy (±GC) (%)	24 (18.0)	9 (34.6)	15 (14.0)	**0.02**
Last visit (%)				
Methotrexate	26 (19.5)	7 (26.9)	19 (17.8)	0.29
Salazopyrine	3 (2.3)	0	3 (2.8)	1
Hydroxychloroquine	62 (46.6)	8 (30.8)	54 (50.5)	0.07
Leflunomide	69 (51.9)	7 (26.9)	62 (57.9)	**0.005**
Glucocorticoid	107 (80.5)	17 (65.4)	90 (84.1)	**0.03**
Glucocorticoid (%)				0.12
-<5 mg	27/107 (25.2)	7/17 (41.2)	20/90 (22.2)	
-≥5 mg	80/107 (74.8)	10/17 (58.8)	70/90 (77.8)	
First-visit disease activity				
ESR (mm/h) (SD)	31.4 (22.8)	26.2 (21.4)	33.3 (22.7)	0.16
CRP (mg/dL) (IQR)	1.15 (2.1)	0.9 (1.3)	1.3 (2.7)	0.32
DAS28 CRP (SD)	4.75 (1.5)	4.7 (1.5)	4.8 (1.5)	0.79
HAQ (SD)	1.22 (0.6)	1.15 (0.6)	1.23 (0.6)	0.57
Swollen joint (SJ) (IQR)	1.0 (4.0)	1.5 (5.0)	0.5 (3.3)	0.16
Tender joint (TJ) (IQR)	5.0 (11.0)	5.5 (8.8)	5.0 (11.0)	0.88
- Patient global assessment (VAS) (IQR)	80.0 (30.0)	72.5 (35.0)	80.0 (30.0)	0.86
Last-visit disease activity				
- ESR (IQR)	18.5 (31.5)	10.0 (26.5)	21.0 (31.0)	0.06
- CRP (IQR)	0.65 (1.2)	0.43 (0.7)	0.70 (1.3)	0.19
- DAS28 CRP (IQR)	3.6 (2.3)	2.8 (2.9)	3.8 (2.3)	0.19
- HAQ (IQR)	1.05 (1.2)	0.8 (1.5)	1.1 (1.2)	0.27
- Swollen joint (SJ) (IQR)	0 (1.0)	0 (1.5)	0 (1.0)	0.82
- Tender joint (TJ) (IQR)	1.0 (6.0)	1.0 (5.5)	1.0 (6.0)	0.54
- Patient global assessment (VAS) (IQR)	50.0 (40.0)	50.0 (55.0)	60.0 (40.0)	0.35
DAS28 CRP, first visit (%)				0.11
≤3.2	17/116 (14.7)	6/24 (25.0)	11/92 (12.0)	
>3.2	99/116 (85.3)	18/24 (75.0)	81/92 (88.0)	
DAS28 CRP, last visit (%)				**0.01**
≤3.2	47/122 (38.5)	15/25 (60.0)	32/97 (33.0)	
>3.2	75/122 (61.5)	10/25 (40.0)	65/97 (67.0)	
EULAR good response index (%)				0.11
Good response	34/71 (47.9)	12/18 (66.7)	22/53 (41.5)	
Moderate response	20/71 (28.2)	2/18 (11.1)	18/53 (34.0)	
Poor response	17/71 (23.9)	4/18 (22.2)	13/17 (24.5)	
MACE (%)	4/130 (3.1)	1/23 (4.3)	3 (2.8)	0.54
DVT (%)	2/130 (1.5)	0	2 (1.9)	1
PTE (%)	4/130 (3.1)	1/23 (4.3)	3 (2.8)	0.54

BMI: Body mass index, CAD: Coronary artery disease, CKD: Chronic kidney disease,GC: Glucocorticoid, CRP: C-reactive protein, HAQ: The health assessment questionnaire,VAS: Visual analogue scale, TG: Triglyceride, HDL: High density lipoprotein, LDL: Low density lipoprotein, MACE: Major adverse cardiovascular event, DVT: Deep vein thrombosis, PTE: Pulmonary thromboembolism

Supplementary Table 2. Clinical and demographic characteristics of patients treated with baricitinib: Baricitinib monotherapy and combination therapy			
	Baricitinib monotherapy (n=24)	**Baricitinib+csDMARD (n=62)**	**p**
Female n (%)	18 (75)	50 (80.6)	0.56
Age (SD)	49.1 (15.1)	53.8 (13.1)	0.16
Disease duration, years (SD)	6.2 (4.1)	12.4 (9.2)	**<0.001**
Smoking (%) -Never -Ex-smoker or active smoker	 13 (33.3) 8 (19)	 26 (66.7) 34 (81)	0.14
BMI (SD)	26.3 (4.9)	27.8 (5.6)	0.27
BMI ≥30 (%)	2 (9.5)	19 (33.9)	**0.03**
Hypertension (%)	9/21 (42.9)	23/59 (39)	0.75
Diabetes n (%)	3/21 (14.3)	14/59 (22.8)	0.53
Hyperlipidemia n (%)	10/21 (47.6)	27/59 (45.8)	0.88
CKD n (%)	2/21 (9.5)	4/59 (6.8)	0,65
Positive RF n (%)	14 (58.3)	44 (71)	0.46
Positive CCP n (%)	11/22 (50)	38 (79.2)	**0.01**
Duration of barcitinib, months (med, IQR)	6.3 (5.7)	6 (5.7)	0.79
First-visit disease activity • ESR (mm/h) (SD) • CRP (mg/dL) (IQR) • DAS28 CRP (SD) • HAQ (SD) • Swollen joint (SJ) (IQR) • Tender joint (TJ) (IQR) • Patient global assessment (VAS) (IQR)	 25.6 (20.5) 0.73 (9.5) 4.3 (1.7) 0.9 (0.6) 1 (13) 4 (22) 60 (90)	 29.1 (20.1) 0.9 (12) 4.2 (1.4) 1.1 (0.7) 1 (9) 3 (26) 60 (90)	 0.50 0.75 0.69 0.27 0.17 0.36 0.76
Last-visit disease activity • ESR (IQR) • CRP (IQR) • DAS28 CRP (IQR) • HAQ (IQR) • Swollen joint (SJ) (IQR) • Tender joint (TJ) (IQR) • Patient global assessment (VAS) (IQR)	 9 (56) 0.4 (9.6) 2.4 (5.8) 0.8 (2.2) 0 (6) 1 (22) 50 (100)	 15 (78) 0.6 (18.6) 3.2 (6.3) 1 (2.3) 0 (8) 1 (20) 50 (100)	 **0.02** 0.15 0.17 0.27 0.64 0.94 0.42
DAS28 CRP, first visit (%) ≤3.2 >3.2	 3/19 (15.8) 16/19 (84.2)	 13/50 (26) 37/50 (74)	0.52
DAS28 CRP, last visit (%) ≤3.2 >3.2	 12/21 (57.1) 9/21 (45.8)	 25/53 (47.2) 28/53 (52.8)	0.43
EULAR good response index (%) good response moderate response poor response	 10 (52.6) 1 (5.3) 8 (42.1)	 14 (29.2) 3 (6.3) 31 (64.6)	0.19
Last visit (SD) -TG -HDL -Kolesterol -LDL	 134.4 (49) 59.8 (18.1) 213.8 (43.4) 133.3 (32.4)	 125 (76) 56.6 (16.5) 199.8 (52.6) 132.4 (52.9)	 0.63 0.48 0.30 0.94
MACE (%)	1/21 (4.8)	1/59 (1.7)	0.45
DVT (%)	0	0	

BMI: Body mass index, CAD: Coronary artery disease, CKD: Chronic kidney disease,GC: Glucocorticoid, CRP: C-reactive protein, HAQ: The health assessment questionnaire,VAS: Visual analogue scale, TG: Triglyceride, HDL: High density lipoprotein, LDL: Low density lipoprotein, MACE: Major adverse cardiovascular event, DVT: Deep vein thrombosis, PTE: Pulmonary thromboembolism

Supplementary Table 3. Clinical and demographic characteristics of patients treated with baricitinib: Biological experienced and non-biological experienced				
	All patients	**Non-biological experienced (n=26)**	**Biological experienced (n=60)**	**p**
Female n (%)	68 (79.1)	20 (76.9)	48 (80)	0.74
Age (SD) 52.5 (13.8) 51.5 (13.6) 52.9 (14)				0.68
Disease duration, years (SD)	10.7 (8.5)	8 (9.3)	11.9 (8)	**0.05**
Disease duration at the time of the first biologic drug: years (SD)	6 (7.2)	7.5 (9.2)	5.3 (6)	0.27
Smoking (%) -Never -Ex-smoker or active smoker	 39 (48.1) 42 (51.9)	 8 (34.8) 15 (65.2)	 31 (53.4) 27 (46.6)	0.13
BMI (SD)	27.4 (5.4)	28.5 (5.6)	27 (5.4)	0.25
BMI ≥30 (%)	23 (26.7)	9 (34.6)	14 (23.3)	0.27
Hypertension (%)	32/80 (40)	8 (34.8)	24 (42.1)	0.54
Diabetes n (%)	17/80 (21.3)	4 (17.4)	13 (22.8)	0.76
Hyperlipidemia n (%)	37/80 (46.3)	13 (56.5)	24 (42.1)	0.24
CKD n (%)	6/80 (7.5)	2 (8.7)	4 (7)	1
Positive RF n (%)	58/82 (70.7)	15 (62.5)	43 (74.1)	0.29
Positive CCP n (%)	49/70 (70)	18 (81.8)	31 (64.6)	0.14
Duration of barcitinib, months (med, IQR)	6.9 (7.4)	4.4 (6.3)	7.5 (6.5)	0.09
Monotherapy (±GC) (%)	24 (27.9)	9 (34.6)	15 (25)	0.36
Last visit (%) • Methotrexate • Salazopyrine • Hydroxychloroquine • Leflunomide • Glucocorticoid	17 (19.8) 1 (1.2) 27 (31.4) 38 (44.2) 59 (68.6)	7 (26.9) 0 8 (30.8) 7 (26.9) 17 (65.4)	10 (16.7) 1 (1.7) 19 (31.7) 31 (51.7) 42 (70)	0.27 1 0.93 **0.03** 0.6
First-visit disease activity • ESR (mm/h) (SD) • CRP (mg/dL) (IQR) • DAS 28 CRP (SD) • HAQ (SD) • Swollen joint (SJ) (IQR) • Tender joint (TJ) (IQR) • Patient global assessment (VAS) (IQR)	28.1 (20.2) 0.9 (1.1) 4.2 (1.5) 1 (0.6) 1 (3) 3 (6) 60 (30)	30.5 (22.3) 1.1 (1.1) 4.9 (1.5) 1.1 (0.7) 1.5 (5) 5.5 (8.8) 72.5 (32.5)	29.8 (18.3) 0.74 (1.1) 3.9 (1.5) 0.8 (0.6) 0.5 (2) 3 (5.8) 50.0 (25.0)	0.90 **0.03** **0.02** 0.10 0.06 0.07 **0.009**
Last-visit disease activity • ESR (IQR) • CRP (IQR) • DAS28 CRP (IQR) • HAQ (IQR) • Swollen joint (SJ) (IQR) • Tender joint (TJ) (IQR) • Patient global assessment (VAS) (IQR)	11.5 (30) 0.4 (0.6) 2.7 (2.3) 0.5 (1.3) 0 (0) 0 (3) 50 (40)	9.5 (20.5) 0.4 (0.6) 2.5 (2.4) 0.4 (1.3) 0 (0) 0 (2) 50 (43.0)	12.5 (35.0) 0.4 (0.6) 2.8 (2.3) 0.6 (1.3) 0 (0) 0 (3.3) 50 (40)	0.40 0.90 0.59 0.67 0.66 0.54 0.72
DAS28 CRP, first visit (%)				0.95
≤3.2 >3.2	16 (23.2) 53 (73.7)	5/22 (22.7) 17/22 (77.3)	11/47 (23.4) 36/47 (76.6)	
DAS 28 CRP, last visit (%) ≤3.2 >3.2	37 (50) 37 (50)	14/23 (61) 9/23 (39)	23/51 (45) 28/51 (55)	0.20
EULAR good response index (%) good response Moderate response Poor response	24 (35.8) 4 (6) 39 (39)	12 (57.1) 2 (9.5) 7 (33.3)	12 (26.1) 2 (4.3) 32 (69.6)	**0.02**
Last visit (SD) -TG -HDL -Cholesterol -LDL	127.2 (70.4) 57.3 (16.8) 203.1 (50.6) 132.6 (48.5)	141.3 (60.6) 51.9 (9.4) 202.4 (55.5) 137.2 (44.7)	122 (73.7) 59.5 (18.6) 203.4 (49) 130.8 (50.2)	0.29 **0.02** 0.93 0.61
MACE (%)	2/80 (2.5)	1/23 (4.3)	1/57 (1.8)	0.49
DVT (%)	0	0	0	
PTE (%)	1/80 (1.3)	1/23 (4.3)	0	0.28

BMI: Body mass index, CAD: Coronary artery disease, CKD: Chronic kidney disease,GC: Glucocorticoid, CRP: C-reactive protein, HAQ: The health assessment questionnaire,VAS: Visual analogue scale, TG: Triglyceride, HDL: High density lipoprotein, LDL: Low density lipoprotein, MACE: Major adverse cardiovascular event, DVT: Deep vein thrombosis, PTE: Pulmonary thromboembolism